Roth Capital Has Negative Outlook for Tilray FY2025 Earnings

Tilray Inc (NASDAQ:TLRY) – Equities research analysts at Roth Capital lowered their FY2025 EPS estimates for Tilray in a report issued on Monday, April 7th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings of ($0.24) per share for the year, down from their previous forecast of ($0.23). The consensus estimate for Tilray’s current full-year earnings is ($0.20) per share.

Tilray (NASDAQ:TLRY) last released its earnings results on Tuesday, April 8th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The company had revenue of $185.78 million during the quarter, compared to the consensus estimate of $213.38 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%.

TLRY has been the topic of several other reports. Piper Sandler cut their price objective on Tilray from $2.00 to $1.00 and set a “neutral” rating on the stock in a research report on Wednesday. Canaccord Genuity Group lifted their price target on Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $2.35.

Tilray Stock Up 16.2 %

Shares of Tilray stock opened at $0.53 on Wednesday. Tilray has a 12-month low of $0.44 and a 12-month high of $2.52. The company has a market cap of $497.05 million, a P/E ratio of -1.77 and a beta of 1.88. The company’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $1.19. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Tilray

Institutional investors and hedge funds have recently made changes to their positions in the business. Lido Advisors LLC purchased a new stake in shares of Tilray in the 4th quarter worth approximately $28,000. Verdence Capital Advisors LLC purchased a new stake in shares of Tilray in the fourth quarter worth $29,000. Dudley Capital Management LLC bought a new position in shares of Tilray during the fourth quarter valued at $29,000. Ameritas Advisory Services LLC bought a new position in shares of Tilray during the fourth quarter valued at $32,000. Finally, Newman Dignan & Sheerar Inc. raised its position in shares of Tilray by 61.9% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 9.35% of the company’s stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.